ASH 2023 | The challenge of treating HMA-refractory MDS patients
Samuel Urrutia
• 9 Dec 2023
Samuel Urrutia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, addresses the challenge of treating patients with myelodysplastic syndromes (MDS) who have failed treatment with hypomethylating agents (HMAs). He suggests that all patients have mutational profiling at the time of relapse to identify any potential therapeutic targets and mentions clinical trials that are currently investigating sabatolimab (NCT03946670, NCT04266301) and HMA plus venetoclax in MDS. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
